Aberdeen Group plc Lowers Stock Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• Aberdeen Group plc cut its stake in BioNTech by 84.9% in Q4, selling 247,847 shares and retaining 44,060 shares worth $4.195 million.
• Analysts display a consensus of "Moderate Buy" with an average target price of $133.07, though BMO and TD Cowen trimmed targets while Deutsche Bank and Goldman Sachs reaffirmed buy ratings.
• Shares opened at $92.08 (52-week range $79.52–$124.00) after BioNTech reported Q results of ($0.39) EPS on $1.06 billion revenue, and analysts forecast -3.88 EPS for the fiscal year.

Aberdeen Group plc cut its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 84.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,060 shares of the company's stock after selling 247,847 shares during the period. Aberdeen Group plc's holdings in BioNTech were worth $4,195,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BNTX. Royal Bank of Canada grew its position in shares of BioNTech by 95.9% during the first quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock worth $653,000 after acquiring an additional 3,514 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of BioNTech during the first quarter worth approximately $167,000. Russell Investments Group Ltd. lifted its holdings in shares of BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company's stock worth $1,178,000 after purchasing an additional 11,064 shares during the period. Invesco Ltd. lifted its holdings in shares of BioNTech by 5.6% during the second quarter. Invesco Ltd. now owns 681,100 shares of the company's stock worth $72,517,000 after purchasing an additional 35,958 shares during the period. Finally, First Trust Advisors LP lifted its holdings in shares of BioNTech by 4.6% during the second quarter. First Trust Advisors LP now owns 331,360 shares of the company's stock worth $35,280,000 after purchasing an additional 14,425 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BNTX has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of BioNTech in a report on Tuesday, March 17th. BMO Capital Markets decreased their price target on BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioNTech in a report on Friday, January 9th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of BioNTech in a report on Wednesday, March 11th. Finally, TD Cowen decreased their price target on BioNTech from $116.00 to $94.00 and set a "hold" rating for the company in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $133.07.

BioNTech Trading Up 2.7%

Shares of BNTX stock opened at $92.08 on Thursday. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a market cap of $23.14 billion, a P/E ratio of -17.57 and a beta of 1.58. The business has a fifty day simple moving average of $99.67 and a 200-day simple moving average of $101.10. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The firm had revenue of $1.06 billion during the quarter. On average, analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.